- ROUNDTABLE: Pharmacy’s future in sync with technology
- Mylan launches generic version of Detrol LA
- CVS Caremark to stop selling tobacco in all store locations
- EXPERT BLOG: Provider status for pharmacists — one way or another
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
NORTHBROOK, Ill. — The U.S. subsidiary of Japanese drug maker Astellas Pharma has made a drug for overactive bladder available in U.S. pharmacies, the company said.
Astellas Pharma US announced the availability of Myrbetriq (mirabegron) extended-release tablets. The drug is used to treat OAB with symptoms of urge urinary incontinence, urgency and urinary frequency. The Food and Drug Administration approved the drug on June 28, 2012.
"The availability of Myrbetriq marks an important milestone in our ongoing commitment to urology," Astellas SVP sales and marketing Jim Robinson said. "We are pleased to now be able to provide a portfolio of treatment options for those living with overactive bladder."